DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2246931/viking-vktx-up-17-on-encouraging-oral-obesity-drug-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2246931 Mar 27, 2024 - Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days. 0

https://www.zacks.com/commentary/2255375/top-analyst-reports-for-microsoft-novo-nordisk-united-parcel?cid=CS-ZC-FT-research_daily-2255375 Apr 15, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS). 0

https://www.zacks.com/stock/news/2256389/novo-nordisk-nvo-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2256389 Apr 16, 2024 - In the latest trading session, Novo Nordisk (NVO) closed at $123.46, marking a -0.36% move from the previous day. 0

https://www.zacks.com/stock/news/2193794/crispr-crsp-to-focus-on-next-generation-car-t-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193794 Dec 05, 2023 - Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates. 0

https://www.zacks.com/stock/news/2193796/alterity-athe-up-on-preclinical-parkinson-s-treatment-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193796 Dec 05, 2023 - Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease. 0

https://www.zacks.com/stock/news/2194285/pfizer-pfe-arvinas-post-upbeat-data-from-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2194285 Dec 06, 2023 - Interim data from an early-stage study shows that treatment with Pfizer (PFE)/Arvinas' (ARVN) breast cancer combination therapy demonstrates encouraging clinical activity in heavily pre-treated patients. 0

https://www.zacks.com/stock/news/2195115/pharvaris-phvs-stock-up-18-on-hae-drug-meeting-study-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195115 Dec 07, 2023 - Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%. 0

https://www.zacks.com/stock/news/2195640/merck-s-mrk-keytruda-lynparza-combo-fails-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195640 Dec 08, 2023 - After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC. 0

https://www.zacks.com/stock/news/2196988/lly-down-as-patients-regain-weight-after-stopping-zepbound?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196988 Dec 12, 2023 - Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight. 0

https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199316 Dec 18, 2023 - Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024. 0